Pre-Clinical & Discovery Stage
Gap
Critical need for more and better PTSD treatment options PTSD costs society billions in health care & lost productivity
Rationale
Address a long felt need for a treatment & ROA designed for the psychiatrist’s office Develop an indication that expands beyond TRD, which is becoming crowded with empathogens & 5HT2A agonists
Market Opportunity
$2.3B global1
1 Coherent Market Research
Gap
DMT is the prototypical psychedelic but:
Rationale
DMT shows strong potential in mental health if you can control entry, altitude and exit of the experience. Bexson's Sub-Q DMT + pump can manage this gracefully.
Market Opportunity
$1.2B global1
1 Coherent Market Research
Gap
IV-only infusion treatments are very expensive.4 Requires in-clinic IV administration or very expensive at home services.
Rationale
Moving from IV to SubQ wearable delivery will improve patient safety & convenience. Large cost savings by removing clinic and daily IV services. 505b2 regulatory pathway
Market Opportunity
>$1.5B U.S.5
4 JAMA Network Open. 2022
5 Research and Markets (Dec 2021)